The anti-inflammatory mechanisms appear to be independent of weight loss or glycemic improvement, suggesting direct immunomodulatory properties
By linking privacy-protected pharmacy records, HealthVerity Marketplace includes prescription data on more than 19.1 million patients taking GLP-1 drugs such as Ozempic, semaglutide, and Rybelsus
In the general obesity population, cost-effectiveness is highly sensitive to drug price, treatment duration, and reimbursement context, and published models have reached variable conclusions (201203)
Another factor involves metabolic differences between individuals
Further reading: Oh Oh Oh Ozempic-is there anything GLP-1 drugs cant do
Increasingly, for-profit telehealth companies are filling the void